Dr Basak Yakis-Douglas
Oxailis uses an AI-based software that metricates tissue perfusion from 3D ultrasound scans.
Project
Oxailis
URL
Year founded
2025
Business stage
Pre-Seed
High-growth sectors
Digital and Technologies
Sector
Health
Location
South East
Funding
Highly Commended Applicant
The problem and opportunity
Many clinical decisions depend on knowing how blood moves through tissue, yet perfusion is hard to assess routinely and objectively. Hospitals often rely on indirect signs, specialist interpretation or late indicators of deterioration. This affects patients, clinicians and health systems, including maternity care, where earlier insight into placental function could improve risk assessment.
The solution and innovation
Oxailis has developed a software-only AI platform that analyses 3D power Doppler ultrasound data to extract rapid, objective measures of tissue perfusion. Its first product, OxNNet Toolkit Placenta, is built on data from more than 7,500 pregnancies and processes scans in under five seconds. The technology is proprietary, IP-protected and designed to work with existing ultrasound systems.
Market and ambition
Our initial market is maternity care, working with hospitals, fetal medicine units and ultrasound manufacturers. Over the next 2-3 years, we aim to complete regulatory approval, validate the platform across major ultrasound vendors and establish Oxailis as a clinical AI platform for perfusion assessment.
Founder perspective
Dr Basak Yakis-Douglas is a strategy scholar and entrepreneur specialising in how science-based ventures enter regulated markets. She co-founded Oxailis to move a powerful clinical AI technology from research into safe, scalable healthcare use that delivers social impact.
Women in Innovation Award
Highly Commended Applicant of the Innovate UK Women in Innovation Award 2025/26, receiving tailored business support and access to specialist training and networks. View all winners and highly commended applicants from the Women in Innovation cohort 2025/2026.